Sanofi (NASDAQ: SNY) has announced the discontinuation of its antibody-drug conjugate (ADC) tusamitamab ravtansine following disappointing results from a Phase III trial in metastatic non-squamous (NSq) non-small cell lung cancer (NSCLC) patients with high CEACAM5 expression. The trial did not meet its dual primary endpoints, as indicated by an interim analysis from an independent data monitoring committee (IDMC). The monotherapy showed no improvement in progression-free survival (PFS) when compared to docetaxel, although it did achieve the dual primary outcome of increasing overall survival (OS) and demonstrated a favorable safety profile.
Despite this setback, Sanofi remains committed to investigating CEACAM5 as an oncology biomarker and to the development of tusamitamab-based ADCs in the fight against cancer.- Fineline.com
